1. Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Mark J. Speakman 
European Urology Supplements 
Volume 3, Issue 4, Pages (September 2004)
DOI: /j.eursup
Copyright © 2004 Elsevier B.V. Terms and Conditions

2. Fig. 1
Percentage of 107 urologists indicating that they prescribe a particular medical therapy at least frequently (i.e. >50% of patients) or regularly (i.e. >25% of patients) [11]. alpha-AR: α1-AR antagonist, 5alpha-RI: 5α-reductase inhibitor, Plant: plant extract.
European Urology Supplements 2004 3, 18-22DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

3. Fig. 2
Preferred medical therapy for patients at low, intermediate and high risk of progression in web-based survey among 77 European urologists [11]. alpha-AR: α1-AR antagonist, 5alpha-RI: 5α-reductase inhibitor, Plant: plant extract.
European Urology Supplements 2004 3, 18-22DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

4. Fig. 3
Example of theoretical patient case in electronic rating programme used for the RAM study [14].
European Urology Supplements 2004 3, 18-22DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

5. Fig. 4
Panel judgements (%) on appropriateness of 7 treatments vs. continuous use of an α1-AR antagonist [14].
European Urology Supplements 2004 3, 18-22DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions